Erratum: Oral anticoagulants for Asian patients with atrial fibrillation (Nature Reviews Cardiology (2014) 11 (290-303) DOI: 10.1038/nrcardio.2014.22);Oral anticoagulants for Asian patients with atrial fibrillation

Nature Reviews Cardiology

Volumn 11, Issue 5, 2014, Pages 290-303

  Sabir, Ian ^a   Khavandi, Kaivan ^a   Brownrigg, Jack ^b   Camm, A John ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; VITAMIN K GROUP;

ANTICOAGULATION; ASIAN; CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); COMPLICATION; EPIDEMIOLOGY; ETHNOLOGY; EVIDENCE BASED MEDICINE; INCIDENCE; MORTALITY; ORAL DRUG ADMINISTRATION; PREVALENCE; STATISTICS AND NUMERICAL DATA; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ANTITHROMBINS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; PREVALENCE; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84899638152     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.134     Document Type: Erratum

References (143)

1. Lip, G. Y., Brechin, C. M. & Lane, D. A. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 142, 1489-1498 (2012
2. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22, 983-988 (1991
3. Wang, T. J. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 107, 2920-2925 (2003
4. Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 98, 946-952 (1998
5. Santangeli, P. et al. Atrial fibrillation and the risk of incident dementia: A meta-Analysis. Heart Rhythm 9, 1761-1768 (2012
6. Iwasaki, Y. K., Nishida, K., Kato, T. & Nattel, S. Atrial fibrillation pathophysiology: Implications for management. Circulation 124, 2264-2274 (2011
7. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840-844 (1994
8. Krahn, A. D., Manfreda, J., Tate, R. B., Mathewson, F. A. & Cuddy, T. E. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98, 476-484 (1995
9. Gami, A. S. et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110, 364-367 (2004
10. Watanabe, H. et al. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circulation 117, 1255-1260 (2008
11. Fox, C. S. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 291, 2851-2855 (2004
12. Lubitz, S. A. et al. Genetics of atrial fibrillation: Implications for future research directions and personalized medicine. Circ. Arrhythm. Electrophysiol. 3, 291-299 (2010
13. Lloyd-Jones, D. et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 121, e46-e215 (2010
14. Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-Term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113, 359-364 (2002
15. Kim, M. H., Johnston, S. S., Chu, B. C., Dalal, M. R. & Schulman, K. L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ. Cardiovasc. Qual. Outcomes 4, 313-320 (2011
16. Feinberg, W. M., Blackshear, J. L., Laupacis, A., Kronmal, R. & Hart, R. G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155, 469-473 (1995
17. Heeringa, J. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur. Heart J. 27, 949-953 (2006
18. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370-2375 (2001
19. Chugh, S. S., Blackshear, J. L., Shen, W. K., Hammill, S. C. & Gersh, B. J. Epidemiology and natural history of atrial fibrillation: Clinical implications. J. Am. Coll. Cardiol. 37, 371-378 (2001
20. Lloyd-Jones, D. M. et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 110, 1042-1046 (2004
21. Kakkar, A. K. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE 8, e63479 (2013
22. Mathur, R. et al. Ethnicity and stroke risk in patients with atrial fibrillation. Heart 99, 1087-1092 (2013
23. Lip, G. Y. et al. Atrial fibrillation amongst the Indo Asian general practice population. The West Birmingham Atrial Fibrillation Project. Int. J. Cardiol. 65, 187-192 (1998
24. Zhou, Z. & Hu, D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J. Epidemiol. 18, 209-216 (2008
25. Inoue, H. et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int. J. Cardiol. 137, 102-107 (2009
26. Lau, C. P. et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J. Cardiovasc. Electrophysiol. 24, 381-387 (2013
27. Tsai, C. F., Thomas, B. & Sudlow, C. L. Epidemiology of stroke and its subtypes in Chinese vs white populations: A systematic review. Neurology 81, 264-272 (2013
28. Kim, A. S. & Johnston, S. C. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 124, 314-323 (2011
29. Gunarathne, A. et al. Ischemic stroke in South Asians: A review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke 40, e415-e423 (2009
30. Steg, P. G. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297, 1197-1206 (2007
31. Ducrocq, G. et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: Results from the REACH Registry. Eur. J. Prev. Cardiol. http://dx.doi.org/10.1177/2047487313501278
32. Khan, N. A. et al. Risk factors, quality of care and prognosis in South Asian, East Asian and White patients with stroke. BMC Neurol. 13, 74 (2013
33. Sen, S. et al. Racial-ethnic differences in stroke risk factors and subtypes: Results of a prospective hospital-based registry. Int. J. Neurosci. 123, 568-574 (2013
34. Goto, S. et al. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. Results from the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ. J. 75, 2598-2604 (2011
35. Li, S. Y. et al. One-year clinical prediction in Chinese ischemic stroke patients using the CHADS2 and CHA2DS2-VASc scores: The China National Stroke Registry. CNS Neurosci. Ther. 18, 988-993 (2012
36. Toda, E. et al. Use of the CHADS2 and CHA2DS2-VASC score in Japanese patients with atrial fibrillation, coronary or cerebrovascular events (J-TRACE). J. Am. Coll. Cardiol. 59, E674 (2012
37. Yap, K. B., Ng, T. P. & Ong, H. Y. Low prevalence of atrial fibrillation in community-Dwelling Chinese aged 55 years or older in Singapore: A population-based study. J. Electrocardiol. 41, 94-98 (2008
38. Tanizaki, Y. et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: The Hisayama study. Stroke 31, 2616-2622 (2000
39. Chien, K. L. et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int. J. Cardiol. 139, 173-180 (2010
40. Lip, G. Y., Kamath, S., Jafri, M., Mohammed, A. & Bareford, D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: The West Birmingham Atrial Fibrillation Project. Stroke 33, 238-242 (2002
41. Zhao, D. et al. Epidemiological transition of stroke in China: Twenty one year observational study from the Sino MONICA Beijing Project. Stroke 39, 1668-1674 (2008
42. Kubo, M. et al. Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 66, 1539-1544 (2006
43. Greenberg, S. M. et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol. 8, 165-174 (2009
44. Koennecke, H. C. Cerebral microbleeds on MRI: Prevalence, associations, and potential clinical implications. Neurology 66, 165-171 (2006
45. Bokura, H. et al. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 42, 1867-1871 (2011
46. Lee, S. H., Ryu, W. S. & Roh, J. K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 72, 171-176 (2009
47. Suzuki, S. et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ. J. 71, 761-765 (2007
48. Veenstra, D. L. et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005
49. Hyun, K. K. et al. A comparative analysis of risk factors and stroke risk for Asian and non-Asian men: The Asia Pacific cohort studies collaboration. Int. J. Stroke 8, 606-611 (2013
50. Investigators, A. F. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994
51. van Walraven, C. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-Analysis. JAMA 288, 2441-2448 (2002
52. Holbrook, A. M. et al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165, 1095-1106 (2005
53. Aithal, G. P., Day, C. P., Kesteven, P. J. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999
54. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-Anticoagulant effect of warfarin. Blood 105, 645-649 (2005
55. Kimmel, S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013
56. Verhoef, T. I. et al. A randomized trial of genotype guided dosing of acenocoumarol and phenprocoumon. N. Engl. J. Med. 369, 2304-2312 (2013
57. Pirmohamed, M. et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013
58. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009
59. Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011
60. Albertsen, I. E. et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-Analysis. Stroke 44, 1329-1336 (2013
61. Guo, Y. et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact? Int. J. Cardiol. 168, 515-522 (2012
62. Hori, M. et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44, 1891-1896 (2013
63. Goto, S. et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia. Eur. Heart J. 34, 1039 (2013
64. Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011
65. Goto, S. et al. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights. Eur. Heart J. 34, 790-791 (2013
66. Sato, H. et al. Low-Dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37, 447-451 (2006
67. Shinohara, Y. et al. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 9, 959-968 (2010
68. Kamal, A. K., Naqvi, I., Husain, M. R. & Khealani, B. A. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD008076. http://dx.doi.org/10.1002/14651858.CD008076.pub2
69. Wan, Y. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ. Cardiovasc. Qual. Outcomes 1, 84-91 (2008
70. Rose, A. J., Ozonoff, A., Grant, R. W., Henault, L. E. & Hylek, E. M. Epidemiology of subtherapeutic anticoagulation in the United States. Circ. Cardiovasc. Qual. Outcomes 2, 591-597 (2009
71. Bode, W. et al. The refined 1.9 A crystal structure of human alpha-Thrombin: Interaction with D Phe Pro-Arg chloromethylketone and significance of the Tyr Pro Pro-Trp insertion segment. EMBO J. 8, 3467-3475 (1989
72. Di Nisio, M., Middeldorp, S. & Buller, H. R. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040 (2005
73. Lee, C. J. & Ansell, J. E. Direct thrombin inhibitors. Br. J. Clin. Pharmacol. 72, 581-592 (2011
74. Ho, S. J. & Brighton, T. A. Ximelagatran: Direct thrombin inhibitor. Vasc. Health Risk Manag. 2, 49-58 (2006
75. Albers, G. W. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293, 690-698 (2005
76. AstraZeneca. AstraZeneca Decides to Withdraw Exanta™ [online], http://www.astrazeneca.com/Media/Press-releases/Article/20060214-AstraZeneca- Decides-To-Withdraw-Exanta (2006
77. Olsson, S. B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 362, 1691-1698 (2003
78. Deinum, J., Mattsson, C., Inghardt, T. & Elg, M. Biochemical and pharmacological effects of the direct thrombin inhibitor AR H067637. Thromb. Haemost. 101, 1051-1059 (2009
79. Lip, G. Y. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur. Heart J. 30, 2897-2907 (2009
80. Olsson, S. B. et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb. Haemost. 103, 604-612 (2010
81. Lip, G. Y. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb. Res. 127, 91-99 (2011
82. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386-399 (2008
83. Ezekowitz, M. D. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100, 1419-1426 (2007
84. Hori, M. et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub analysis in Japanese population in RE LY trial. Circ. J. 75, 800-805 (2011
85. Hartter, S., Yamamura, N., Stangier, J., Reilly, P. A. & Clemens, A. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb. Haemost. 107, 260-269 (2012
86. Yeh, C. H., Fredenburgh, J. C. & Weitz, J. I. Oral direct factor Xa inhibitors. Circ. Res. 111, 1069-1078 (2012
87. Buller, H. R. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349, 1695-1702 (2003
88. Yusuf, S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354, 1464-1476 (2006
89. Padmanabhan, K. et al. Structure of human des(1-45) factor Xa at 2.2 A resolution. J. Mol. Biol. 232, 947-966 (1993
90. Perzborn, E., Roehrig, S., Straub, A., Kubitza, D. & Misselwitz, F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 10, 61-75 (2011
91. Perzborn, E. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59 7939-An oral, direct factor Xa inhibitor. J. Thromb. Haemost. 3, 514-521 (2005
92. Depasse, F. et al. Effect of BAY 59-7939-A novel, oral, direct Factor Xa inhibitor-on clot bound Factor Xa activity in vitro [abstract]. J. Thromb. Haemost. 3 (Suppl. 1), P1104 (2005
93. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M. & Wensing, G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78, 412-421 (2005
94. Kubitza, D., Becka, M., Wensing, G., Voith, B. & Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59 7939-An oral, direct factor Xa inhibitor-After multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880 (2005
95. Jiang, J. et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-An oral, direct factor Xa inhibitor-in elderly Chinese subjects. Thromb. Haemost. 103, 234-241 (2010
96. Zhao, X. et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br. J. Clin. Pharmacol. 68, 77-88 (2009
97. Stampfuss, J., Kubitza, D., Becka, M. & Mueck, W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int. J. Clin. Pharmacol. Ther. 51, 549-561 (2013
98. Hori, M. et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-The J ROCKET AF study. Circ. J. 76, 2104-2111 (2012
99. Hori, M. et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Subanalysis of J ROCKET AF for patients with moderate renal impairment. Circ. J. 77, 632-638 (2013
100. Lee, M. et al. Low glomerular filtration rate and risk of stroke: Meta-Analysis. BMJ 341, c4249 (2010
101. Alonso, A. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 123, 2946-2953 (2011
102. Olesen, J. B. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367, 625-635 (2012
103. Lassen, M. R. et al. A phase II randomized, double-blind, five-Arm, parallel-group, dose-response study of a new oral directly acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery (ASH Annual Meeting Abstracts) [abstract 41]. Blood 102, 41 (2003
104. Wong, P. C. et al. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-Dose antithrombotic activity without enhancing bleeding liability in rabbits. J. Thromb. Thrombolysis 24, 43-51 (2007
105. Wong, P. C. et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6, 820-829 (2008
106. Jiang, X., Crain, E. J., Luettgen, J. M., Schumacher, W. A. & Wong, P. C. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb. Haemost. 101, 780-782 (2009
107. Frost, C. et al. Apixaban, a direct factor Xa inhibitor: Single-Dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 142]. Br. J. Clin. Pharmacol. 48, 1132 (2008
108. Frost, C. et al. Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol. 75, 476-487 (2013
109. Vakkalagadda, B. et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract 143]. J. Clin. Pharmacol. 49, 1124 (2009
110. Easton, J. D. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 11, 503-511 (2012
111. Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1 year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 138, 1093-1100 (2010
112. Lopes, R. D. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial. Lancet 380, 1749-1758 (2012
113. Ogawa, S., Shinohara, Y. & Kanmuri, K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE J study. Circ. J. 75, 1852-1859 (2011
114. Connolly, S. J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011
115. Hara, T. et al. DX 9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemost. 71, 314-319 (1994
116. Fujii, Y. et al. Characteristics of gastrointestinal absorption of DX 9065a, a new synthetic anticoagulant. Drug Metab. Pharmacokinet. 22, 26-32 (2007
117. Zafar, M. U. et al. Antithrombotic effects of factor Xa inhibition with DU 176b: Phase I study of an oral, direct factor Xa inhibitor using an ex vivo flow chamber. Thromb. Haemost. 98, 883-888 (2007
118. Furugohri, T. et al. DU 176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 6, 1542-1549 (2008
119. Matsushima, N., Lee, F., Sato, T., Weiss, D. & Mendell, J. Bioavailability and safety of the factor xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin. Pharm. Drug Dev. 2, 358 (2013
120. Giugliano, R. P. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369, 2093-2104 (2013
121. Yamashita, T. et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ. J. 76, 1840-1847 (2012
122. Chung, N. et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb. Haemost. 105, 535-544 (2011
123. Mendell, J., Tachibana, M., Shi, M. & Kunitada, S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J. Clin. Pharmacol. 51, 687-694 (2011
124. Ahrens, I., Peter, K., Lip, G. Y. & Bode, C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov. Med. 13, 445-450 (2012
125. Palladino, M., Merli, G. & Thomson, L. Evaluation of the oral direct factor Xa inhibitor-betrixaban. Expert Opin. Investig. Drugs 22, 1465-1472 (2013
126. Connolly, S. J. et al. Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur. Heart J. 34, 1498-1505 (2013
127. Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446-451 (2013
128. Ansell, J. Blocking bleeding: Reversing anticoagulant therapy. Nat. Med. 19, 402-404 (2013
129. Dentali, F. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-Analysis of the literature. Circulation 126, 2381-2391 (2011
130. Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B. & Eisenberg, M. J. Meta-Analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110, 453-460 (2012
131. Sardar, P. et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: Insights from a meta-Analysis and indirect treatment comparisons. PLoS ONE 8, e77694 (2013
132. Capodanno, D., Capranzano, P., Giacchi, G., Calvi, V. & Tamburino, C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-Analysis of 50,578 patients. Int. J. Cardiol. 167, 1237-1241 (2013
133. Bruins Slot, K. M. & Berge, E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD008980. http://dx.doi.org/10.1002/14651858.CD008980.pub2
134. Rasmussen, L. H., Larsen, T. B., Graungaard, T., Skjoth, F. & Lip, G. Y. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: Indirect comparison analysis. BMJ 345, e7097 (2012
135. Lip, G. Y., Larsen, T. B., Skjoth, F. & Rasmussen, L. H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol. 60, 738-746 (2012
136. Savelieva, I. & Camm, A. J. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin. Cardiol. 37, 32-47 (2014
137. Wallentin, L. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE LY trial. Lancet 376, 975-983 (2010
138. FDA. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) [online], http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf (2011
139. Rosendaal, F. R., Cannegieter, S. C., Van Der Meer, F. J. & Briet, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236-239 (1993
140. You, J. H. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation a cost effectiveness analysis. J. Gen. Intern. Med. http://dx.doi.org/10.1007/s11606-013-2639-2
141. Ogawa, S. et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J. Arryth. 29, 190-200 (2013
142. Group, J. J. Guidelines for pharmacotherapy of atrial fibrillation (JCS2008): Digest version. Circ. J. 74, 2479-2500 (2010
143. Department of Health, Western Australia. Atrial Fibrillation Working Group. Quick Reference Guide: Atrial Fibrillation Information for the Health Practitioner. Perth: Health Networks Branch [online], http://www.healthnetworks. health.wa.gov.au/docs/QuickReferenceGuide-AtrialFibrillation.pdf (2011.